Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries 4D Molecular Therapeutics Inc (NQ: FDMT ) 9.970 -0.370 (-3.58%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 630,017 Open 10.51 Bid (Size) 9.770 (1) Ask (Size) 10.18 (8) Prev. Close 10.34 Today's Range 9.775 - 10.56 52wk Range 9.440 - 36.25 Shares Outstanding 42,052,980 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News 4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference September 23, 2024 Preclinical data for 4D-710 for cystic fibrosis lung disease in combination with CFTR modulators to be presented in a poster presentation From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4D Molecular Therapeutics Stock Falls After Follow-Up Data From Mid-Stage Study Of Vision Loss Drug Candidate September 19, 2024 4D Molecular Therapeutics stock drops after the company shared interim data from the PRISM Phase 1/2 trial and details on its Phase 3 4FRONT study for wet AMD. The Phase 3 study comparing 4D-150 to... Via Benzinga Performance YTD -53.08% -53.08% 1 Month -36.17% -36.17% 3 Month -52.86% -52.86% 6 Month -65.14% -65.14% 1 Year -18.94% -18.94% More News Read More 4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day September 18, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire The Latest Analyst Ratings For 4D Molecular Therapeutics September 09, 2024 Via Benzinga Peeling Back The Layers: Exploring 4D Molecular Therapeutics Through Analyst Insights July 18, 2024 Via Benzinga Assessing 4D Molecular Therapeutics: Insights From 7 Financial Analysts June 26, 2024 Via Benzinga Kaskela Law LLC Announces Stockholder Investigation of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) and Encourages Investors to Contact the Firm September 17, 2024 From Kaskela Law LLC Via Business Wire FDMT Investors Have Opportunity to Join 4D Molecular Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm September 12, 2024 From The Schall Law Firm Via Business Wire 4DMT Announces Presentations at Upcoming Retina Conferences September 05, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4DMT to Participate in the 2024 Cantor Global Healthcare Conference September 03, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024 August 27, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference August 12, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire FDMT Stock Earnings: 4D Molecular Therapeutics Beats EPS for Q2 2024 August 09, 2024 Via InvestorPlace 4DMT Reports Second Quarter 2024 Financial Results and Operational Highlights August 08, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4DMT Advances Leadership in Large Market Ophthalmology with Senior Management Hires and Formation of Ophthalmology Advisory Board August 05, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4D Molecular Therapeutics, Inc. (FDMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings July 29, 2024 From Bronstein, Gewirtz & Grossman, LLC Via Business Wire 4D Molecular Therapeutics, Inc. (FDMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings July 21, 2024 From Bronstein, Gewirtz & Grossman, LLC Via Business Wire Why Domino's Pizza Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session July 18, 2024 Via Benzinga FDMT Investors Have Opportunity to Join 4D Molecular Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm July 17, 2024 From The Schall Law Firm Via Business Wire 4D Molecular Therapeutics Goes Neck To Neck With Rival, Shares New Phase 2 Data For Its Wet AMD Candidate July 17, 2024 Via Benzinga 4DMT Announces Positive Phase 2 PRISM Interim Results for Intravitreal 4D-150 in a Broad Wet AMD Population Affirming Favorable Safety Profile and Robust Clinical Activity July 17, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session July 17, 2024 Via Benzinga 4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy June 24, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4DMT to Present Initial Interim 24-week Landmark Analysis from the 4D-150 Phase 2 PRISM Population Extension Cohort in a Broad Wet AMD Population at ASRS and Host a Corporate Webcast June 18, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting June 08, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
